FDA advances first government-funded ibogaine clinical trials for opioid addiction and PTSD

U.S. health agencies are advancing government-funded clinical trials for ibogaine, a Schedule I psychedelic compound, targeting opioid addiction and PTSD. Backed by a $50 million executive order signed by President Donald Trump, HHS and FDA are seeking public feedback on study safety oversight through November 20, 2026. While many Americans currently spend up to $20,000 seeking unregulated treatments in Mexico, experts emphasize resolving fatal cardiac risks remains crucial for official approval.

Federal ibogaine research initiatives

• ▪The Trump administration initiative to advance government-funded ibogaine research follows calls from veterans and experts for strict safety standards on psychedelic treatments.
• ▪The Department of Health and Human Services is funding early-stage clinical trials of ibogaine to treat opioid addiction and post-traumatic stress disorder through ARPA-H and NIDA.
• ▪The U.S. Food and Drug Administration has opened a public docket seeking feedback by November 20, 2026 on trial design, dose selection, patient eligibility, safety monitoring, and oversight for clinical trials of ibogaine.
• ▪President Donald Trump signed an executive order in April 2026 dedicating $50 million in federal funding toward research into the psychedelic drug ibogaine.

Ibogaine Health and cardiac risks

• ▪The Food and Drug Administration has warned that ibogaine carries severe health risks, including life-threatening irregular heart rhythms and potential brain toxicity.
• ▪Multidisciplinary Association for Psychedelic Studies co-executive director Betty Aldworth stated that solving cardiac safety challenges is the central requirement before ibogaine can responsibly reach patients.

Ibogaine treatments in Mexico

• ▪Public attention on ibogaine was renewed following the death of 27-year-old Presley Gerber, who had traveled to Mexico for high-dose treatment while struggling with addiction.
• ▪The New York Times identified at least 40 clinics and wellness centers in Mexico offering ibogaine treatments, ranging from luxury operations with medical staff to informal rustic facilities.
• ▪Due to the lack of approved medical access in the U.S., Americans are paying between $5,000 and $20,000 to travel to specialized clinics in Mexico for ibogaine treatments.

Opioid settlement fund allocations

• ▪In West Virginia, local municipal governments spent nearly half of their allocated opioid settlement funds on general law enforcement expenses in 2024 and 2025.
• ▪Opioid manufacturers and distributors agreed to pay approximately $50 billion to U.S. states and the District of Columbia between 2022 and the late 2030s, with eighty-five per cent required to fund direct opioid remediation.

Debatable claims

• ▪Federal funding for ibogaine clinical trials is justified by its therapeutic potential
• ▪Local governments should not spend opioid settlement funds on general law enforcement expenses